You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)

    SBC: TARGETSITE THERAPEUTICS CORPORATION            Topic: NHLBI

    Abstract. Idiopathic pulmonary fibrosis (IPF) is a progressive fibroproliferative disorder affecting ∼3 million people worldwide with function-limiting progressive symptoms and a 2-3 year median survival time from diagnosis. While the etiology of IPF is not clear, genetic factors, environmental exposures and microbial pathogens have been identified as IPF risk factors. Pirfenidone and nintedanib ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a sample preparation protocol for 3D kidney ultrastructural analysis and immunolabeling by light microscopy

    SBC: panluminate Inc.            Topic: 400

    Abstract The success of cohort studies such as the NIDDK Kidney Precision Medicine Project (KPMP) with its massive amount of samples depends on the cost and time-efficient evaluation of kidney biopsies at multiple scales. Assessing the structure of kidney tissue at the nanoscale (~10 nm) and evaluating the 3-D distribution of protein biomarkers in that context is, however, currently severely limit ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease

    SBC: Recombinant Technologies LLC            Topic: NIA

    Abstract Alzheimer’s disease is the most common cause of dementia and fourth most common cause of death. Amyloid-beta (Aβ) plays a crucial role in initiation and progression of Alzheimer’s disease (AD). Removal of circulating Aβ would shift the equilibrium in Aβ levels between brain and blood towards blood. This shift would deplete brain amyloid levels and improve memory. Three commercial m ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Targeted Damaging Agents for the Treatment of Drug-Resistant Gliomas

    SBC: KL50 THERAPEUTICS, LLC            Topic: 102

    PROJECT SUMMARY Loss of O6-methylguanine methyltransferase (MGMT) expression is common in cancers and confers sensitivity to DNA alkylators, such as temozolomide (TMZ). Epigenetic silencing of MGMT via promoter hypermethylation is found in ~50% of glioblastomas (GBMs), and in most lower grade gliomas with isocitrate dehydrogenase-1/2 (IDH1/2) mutations. MGMT is also silenced in other cancers, incl ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins.

    SBC: ABBRATECH INC.            Topic: 400

    ABSTRACT Antibodies (Abs) are commonly employed in biomedical research to identify and quantify target proteins. However, the specificity, sensitivity and reliability of these Abs can be variable, which is a significant concern in the scientific community. The use of an incorrect Ab can result in misleading or inaccurate results, impeding progress in various areas of biomedical research. In Phase ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. The Alara Imaging Gateway: Linking Electronic Health Records and Radiology Imaging Exams to Report on National Quality Measures to Reduce Cancer Risk from Computed Tomography (Alara Imaging Gateway)

    SBC: ALARA IMAGING INC            Topic: NCI

    Abstract Alara Imaging, Inc. (Alara) is seeking funding to support the development of robust, IP-protected, HIPAA- compliant commercial quality software to calculate and report on quality measures that will be reported for every radiologist and hospital group in the nation. Further, Alara is seeking funding to develop enhanced feedback that leverages machine learning, data visualization, and bench ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A democratized platform for mapping the spatial epigenome in tissue

    SBC: ATLASXOMICS INC            Topic: 100

    PROJECT SUMMARY AtlasXomics Inc. is commercializing the next generation of spatial biology tools to help researchers understand the epigenetic mechanisms of disease. The goal of this SBIR grant is to commercialize a product suite of hardware, consumables, and software to spatially interrogate tissue and generate a new layer of data for better understanding gene expression modulation in tissue. The ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Clinical Optimization of Ultrasonic Drug Delivery Technologies for Underserved Minority US Veterans in Chronic Pain

    SBC: ZETROZ SYSTEMS LLC            Topic: 102

    Project Summary: Narcotic use in pain management of underserved minority populations and minority United States veterans has played a major role in the ongoing opioid crisis. According to the NIH, veterans are more susceptible to opioid addiction and are 40% more likely to suffer from severe chronic joint pain then non-veterans. Over the next decade, the percentage of minority veterans will increa ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    SUMMARY Arboviruses present a constant threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, primarily mosquitoes. One of them, Aedes aegypti, is the primary vector of several widely spread arboviruses such as Zika, dengue and West Nile viruses, and for most of them, human-licensed vaccines do not exist or are suboptimal. These pathogens are transmitted int ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. New Agents for the Treatment on Mycobacteria Avium Infections

    SBC: Quercus Molecular Design, LLC            Topic: NIAID

    Abstract: Non-Tuberculosis Mycobacteria (NTM) are responsible for widespread, life threatening infections of the lungs, skin, lymphatic and hematological systems. The rapid, global spread of resistant organisms has significantly reduced the number of agents that can be used effectively to treat these infections. Of specific clinical relevance are the slow-growing Mycobacterium avium complex (MAC) ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government